{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-006142","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.022217+00:00","generated_at":"2026-06-05T19:35:43.550678+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"C4 Therapeutics reports FY2023 net loss of $132.5M; cash runway extended into 2027","bullets":["Net loss for FY2023 was $132.5M ($2.67 per share) vs $128.2M ($2.62) in FY2022.","Revenue fell to $20.8M from $31.1M, mainly due to end of Calico collaboration.","Cash, equivalents and marketable securities at Dec 31, 2023: $281.7M; proforma ~$330M with Jan 2024 inflows, funding into 2027.","Workforce reduced ~30% in Jan 2024; trials for CFT7455 and CFT1946 continue, data expected 2H2024.","Collaborations: Merck deal up to $2.5B milestone potential; Betta paid $25M, CTA approved in China."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-006142","json":"https://secwatch.observer/filing/0001628280-24-006142.json","markdown":"https://secwatch.observer/filing/0001628280-24-006142.md","text":"https://secwatch.observer/filing/0001628280-24-006142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024006142/0001628280-24-006142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024006142/cccc-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:35:43.550678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"536eba2a3e9143619b949b7c5c33e00cd50ee350","claim":"C4 Therapeutics, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On February 22, 2024, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024006142/0001628280-24-006142-index.htm","confidence":0.65,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}